Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Sep;70(3):434–439. doi: 10.1038/bjc.1994.323

Critical determination of the frequency of c-erbB-2 amplification in breast cancer.

A L Hubbard 1, C P Doris 1, A M Thompson 1, U Chetty 1, T J Anderson 1
PMCID: PMC2033340  PMID: 7915911

Abstract

Tissues from 323 methacarn-fixed and paraffin-embedded breast cancers were assessed for c-erbB-2 gene amplification by differential polymerase chain reaction (dPCR). The sensitivity of dPCR was ascertained using cell lines with c-erbB-2 amplification, and the relationship between dPCR ratio value and gene copy number was established. In clinical material the technique was not affected by the DNA contribution of normal tissue elements or by cancer DNA ploidy change. c-erbB-2 gene amplification was detected in 55% of invasive cancers and in 66% of in situ cancers. c-erbB-2 protein overexpression in breast cancer cells, as determined by specific immunohistochemistry, was only detected in 11% of invasive cancers and 43% of in situ cancers. Comparisons show that a substantial number of cancers with c-erbB-2 amplification lack detectable protein overexpression. This illustrates the complex nature of c-erbB-2 gene disregulation in cancer and suggests that multiple combinations of biological events and consequences are possible.

Full text

PDF
434

Images in this article

436Figure 3
on p.436

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Molina R., Tandon A. K., Schnitt S. J., Gilchrist K. W., Osborne C. K., Tormey D. C., McGuire W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep;23(9):974–979. doi: 10.1016/0046-8177(92)90257-4. [DOI] [PubMed] [Google Scholar]
  2. Anderson T. J. c-erbB-2 oncogene in breast cancer: the right target or a decoy? Hum Pathol. 1992 Sep;23(9):971–973. doi: 10.1016/0046-8177(92)90256-3. [DOI] [PubMed] [Google Scholar]
  3. Band V., Zajchowski D., Stenman G., Morton C. C., Kulesa V., Connolly J., Sager R. A newly established metastatic breast tumor cell line with integrated amplified copies of ERBB2 and double minute chromosomes. Genes Chromosomes Cancer. 1989 Sep;1(1):48–58. doi: 10.1002/gcc.2870010109. [DOI] [PubMed] [Google Scholar]
  4. Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Killander D., McGuire W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15;50(14):4332–4337. [PubMed] [Google Scholar]
  5. Church G. M., Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991–1995. doi: 10.1073/pnas.81.7.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frye R. A., Benz C. C., Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene. 1989 Sep;4(9):1153–1157. [PubMed] [Google Scholar]
  7. Garcia I., Dietrich P. Y., Aapro M., Vauthier G., Vadas L., Engel E. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 1989 Dec 1;49(23):6675–6679. [PubMed] [Google Scholar]
  8. Gullick W. J., Berger M. S., Bennett P. L., Rothbard J. B., Waterfield M. D. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer. 1987 Aug 15;40(2):246–254. doi: 10.1002/ijc.2910400221. [DOI] [PubMed] [Google Scholar]
  9. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  10. Hollywood D. P., Hurst H. C. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J. 1993 Jun;12(6):2369–2375. doi: 10.1002/j.1460-2075.1993.tb05891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hruza C., Dobianer K., Beck A., Czerwenka K., Hanak H., Klein M., Leodolter S., Medl M., Müllauer-Ertl S., Preiser J. HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. Eur J Cancer. 1993;29A(11):1593–1597. doi: 10.1016/0959-8049(93)90301-u. [DOI] [PubMed] [Google Scholar]
  12. Imyanitov E. N., Chernitsa O. I., Serova O. M., Knyazev P. G. Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients. Eur J Cancer. 1992;28A(6-7):1300–1300. doi: 10.1016/0959-8049(92)90501-r. [DOI] [PubMed] [Google Scholar]
  13. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Liu E., Thor A., He M., Barcos M., Ljung B. M., Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992 May;7(5):1027–1032. [PubMed] [Google Scholar]
  15. Lovekin C., Ellis I. O., Locker A., Robertson J. F., Bell J., Nicholson R., Gullick W. J., Elston C. W., Blamey R. W. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991 Mar;63(3):439–443. doi: 10.1038/bjc.1991.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Minty A. J., Caravatti M., Robert B., Cohen A., Daubas P., Weydert A., Gros F., Buckingham M. E. Mouse actin messenger RNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse alpha-actin mRNA. J Biol Chem. 1981 Jan 25;256(2):1008–1014. [PubMed] [Google Scholar]
  17. Neubauer A., Neubauer B., He M., Effert P., Iglehart D., Frye R. A., Liu E. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene. 1992 May;7(5):1019–1025. [PubMed] [Google Scholar]
  18. Perren T. J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer. 1991 Mar;63(3):328–332. doi: 10.1038/bjc.1991.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Poller D. N., Hutchings C. E., Galea M., Bell J. A., Nicholson R. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer. 1992 Sep;66(3):583–588. doi: 10.1038/bjc.1992.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Russell K. S., Hung M. C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 1992 Dec 1;52(23):6624–6629. [PubMed] [Google Scholar]
  21. Sasi R., Hoo J. J., Samuel I. P., Tainaka T., Shiferaw S., Lin C. C. Chromosome aberrations and oncogene alterations in two new breast tumor cell lines. Cancer Genet Cytogenet. 1991 Feb;51(2):239–254. doi: 10.1016/0165-4608(91)90137-j. [DOI] [PubMed] [Google Scholar]
  22. Semba K., Kamata N., Toyoshima K., Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A. 1985 Oct;82(19):6497–6501. doi: 10.1073/pnas.82.19.6497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Singleton T. P., Strickler J. G. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu. 1992;27(Pt 1):165–190. [PubMed] [Google Scholar]
  24. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  25. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  26. Thompson A. M., Steel C. M., Chetty U., Hawkins R. A., Miller W. R., Carter D. C., Forrest A. P., Evans H. J. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer. 1990 Jan;61(1):74–78. doi: 10.1038/bjc.1990.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]
  28. Zhang X., Silva E., Gershenson D., Hung M. C. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene. 1989 Aug;4(8):985–989. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES